ARTICANZ - Beta (ver 0.9)
Annotated Registry of Trials in Cancer, Australia and New Zealand Ed.
- Results - target/PI3K
Home
By cancer type
By drug class
By site
Data
FAQ
About
⚠
ARTICANZ provides informational content about cancer drug trials in Australia/NZ that is updated weekly but may not be completely accurate, and should not replace medical advice from qualified healthcare professionals. The platform is intended to be useful, providing information "as is" without warranties. Non-medical users must always consult healthcare providers for all clinical decisions.
Search results
target/PI3K
6
trial(s) found.
NCT06846671
Haem
Phase 3
Recruiting
A Phase 3, Open-Label, Randomized Study of BGB-16673 Compared to Investigator's Choice (Idelalisib Plus Rituximab or Bendamustine Plus Rituximab or Venetoclax Plus Rituximab Retreatment) in Patients With Chronic Lymphocytic Leukemia Previously Exposed to Both BTK and BCL2 Inhibitors (
BGB-16673-302
)
BCL2 inhibitor
BTK PROTAC degrader
PI3K-delta inhibitor
alkylating agent
anti-CD20 monoclonal antibody
Chronic lymphocytic leukaemia
NSW
2139 - Concord - Concord Repatriation General Hospital
2170 - Liverpool - Liverpool Hospital
2560 - Campbelltown - Macarthur Cancer Therapy Centre - Campbelltown Hospital
VIC
3004 - Melbourne, Southbank - Alfred Health
QLD
4350 - Toowoomba - Toowoomba Hospital
WA
6005 - West Perth - Perth Blood Institute
NZ
NZ.0622 - Takapuna - North Shore Hospital
NCT06208657
Advanced
Phase 1 / Phase 2
Recruiting
Optimal Precision TherapIes to CustoMISE Care in Childhood and Adolescent Cancer (
OPTIMISE
)
Irinotecan
PI3K-delta inhibitor
PI3K alpha inhibitor
PI3K inhibitor
Paxalisib
Temozolomide
alkylating agent
cancer therapy
cancer therapy,PI3K-delta-targeting
cancer therapy,PI3K-targeting
cancer therapy,PI3Kalpha-targeting
cancer therapy,mTOR-targeting
cancer therapy,mTORC1-targeting
cancer therapy,mTORC2-targeting
cytotoxic chemotherapy
dual PI3K/mTOR inhibitor
mTORC1/mTORC2 inhibitor
mTORC1 inhibitor
mTORC2 inhibitor
mTOR inhibitor
topoisomerase inhibitor
+ PI3K-delta inhibitor
Cancer
Central nervous system cancer
Solid tumour
NSW
2031 - Randwick - Sydney Children's Hospital
2145 - Westmead - The Children's Hospital at Westmead
2305 - New Lambton Heights - John Hunter Children's Hospital
VIC
3052 - Parkville - Royal Children's Hospital Melbourne
3168 - Clayton - Monash Children's Hospital
QLD
4101 - South Brisbane - Queensland Children's Hospital
SA
5006 - North Adelaide - Women's and Children's Hospital-Adelaide Cancer Centre
WA
6009 - Perth - Perth Children's Hospital
NCT05501886
Advanced
Phase 3
Recruiting
Phase 3, Open-Label, Randomized, Study Comparing Gedatolisib Combined With Fulvestrant & With or Without Palbociclib to Standard-of-Care Therapies in Patients With HR-Positive, HER2-Negative Advanced Breast Cancer Previously Treated With a CDK4/6 Inhibitor in Combination w/Non-Steroidal Aromatase Inhibitor Therapy (
VIKTORIA-1
)
CDK4/6 inhibitor
pan-PI3K/mTORC1/mTORC2 inhibitor
selective estrogen receptor degrader
Breast cancer
NSW
2076 - Wahroonga - Sydney Adventist Hospital
VIC
3065 - Fitzroy - St Vincent's Hospital Melbourne
3199 - Frankston - Peninsula Health Frankston Hospital (COMPLETED)
QLD
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre
4215 - Southport - Gold Coast Private Hospital
SA
5006 - North Adelaide - Calvary North Adelaide Hospital, Adelaide Oncology & Haematology
5011 - Woodville South - The Queen Elizabeth Hospital
NA
NA
NCT03970447
Advanced
Phase 2 / Phase 3
Recruiting
GBM AGILE: Global Adaptive Trial Master Protocol: An International, Seamless Phase II/III Response Adaptive Randomization Platform Trial Designed To Evaluate Multiple Regimens In Newly Diagnosed and Recurrent GBM (
GBM-AGILE
)
FGFR1/2/3 inhibitor
FGFR1 inhibitor
FGFR2 inhibitor
FGFR3 inhibitor
FGFR4 inhibitor
FGFR inhibitor
KIT/PDGFR/RET/VEGFR/FGFR inhibitor
KIT inhibitor
KIT inhibitor,first generation
Lomustine
PDGFR inhibitor
PI3K-delta inhibitor
PI3K alpha inhibitor
PI3K inhibitor
Paxalisib
Pegargiminase
RET inhibitor
Radiotherapy
Regorafenib
Temozolomide
VAL-083
VEGFR inhibitor
alkylating agent
arginine deiminase-polyethylene glycol conjugate
cancer therapy
cancer therapy,FGFR-targeting
cancer therapy,FGFR1-targeting
cancer therapy,FGFR1/2/3-targeting
cancer therapy,FGFR2-targeting
cancer therapy,FGFR3-targeting
cancer therapy,FGFR4-targeting
cancer therapy,KIT-targeting
cancer therapy,PDGFR-targeting
cancer therapy,PI3K-delta-targeting
cancer therapy,PI3K-targeting
cancer therapy,PI3Kalpha-targeting
cancer therapy,RET-targeting
cancer therapy,VEGFR-targeting
cancer therapy,mTOR-targeting
cancer therapy,mTORC1-targeting
cancer therapy,mTORC2-targeting
cytotoxic chemotherapy
dual PI3K/mTOR inhibitor
mTORC1/mTORC2 inhibitor
mTORC1 inhibitor
mTORC2 inhibitor
mTOR inhibitor
pan-FGFR inhibitor
pan-FGFR inhibitor,reversible
+ PI3K-delta inhibitor
Glioblastoma
NSW
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
QLD
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre
SA
5042 - Bedford Park - Flinders Medical Centre
ACTRN12623000096651
Advanced
Phase 2
Recruiting
LUMOS2
: Low & Anaplastic Grade Glioma Umbrella Study of Molecular Guided TherapieS
Cadonilimab
Niraparib
PARP inhibitor
PI3K-delta inhibitor
PI3K alpha inhibitor
PI3K inhibitor
Paxalisib
Selinexor
XPO1 inhibitor
bispecific PD-1/CTLA4 antibody
cancer therapy
cancer therapy,CTLA4-targeting
cancer therapy,PARP-targeting
cancer therapy,PD-1-targeting
cancer therapy,PD-1/PD-L1-targeting
cancer therapy,PI3K-delta-targeting
cancer therapy,PI3K-targeting
cancer therapy,PI3Kalpha-targeting
cancer therapy,XPO1-targeting
cancer therapy,mTOR-targeting
cancer therapy,mTORC1-targeting
cancer therapy,mTORC2-targeting
dual PI3K/mTOR inhibitor
immune checkpoint blockade
immune checkpoint blockade,CTLA4-targeting
immune checkpoint blockade,PD-1-targeting
immuno-oncology therapy,CTLA4-targeting
immuno-oncology therapy,PD-1-targeting
mTORC1/mTORC2 inhibitor
mTORC1 inhibitor
mTORC2 inhibitor
mTOR inhibitor
therapeutic modality,bispecific antibody
+ PI3K-delta inhibitor
Anaplastic astrocytoma
Low-grade glioma
NSW
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital
2170 - Liverpool - Liverpool Hospital
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3066 - Epping - Northern Hospital
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
3168 - Clayton - Monash Medical Centre
QLD
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre
4102 - Woolloongabba - Princess Alexandra Hospital
SA
5042 - Bedford Park - Flinders Medical Centre
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
TAS
7000 - Hobart - Royal Hobart Hospital
ACTRN12621000991819
Advanced
Not Applicable
Status unknown
A Feasibility Trial of Patient Derived Cell Culture (PDCC) Chemosensitivity in Head and Neck Carcinoma (HNC) (
PDCCiHNC
)
ALK inhibitor
ALK inhibitor,first generation
ATR inhibitor
BCR-ABL1 inhibitor
BCR-ABL1 inhibitor,second generation
CDK4/6 inhibitor
CDK4 inhibitor
CDK6 inhibitor
CRAF/FLT3/KIT/PDGFR/VEGFR inhibitor
CRAF inhibitor
Carboplatin
Ceralasertib
Cisplatin
Crizotinib
Dactolisib
Dasatinib
Docetaxel
Doxorubicin
EGFR inhibitor
EGFR inhibitor,first generation
Erlotinib
Etoposide
FLT3 inhibitor
Fluorouracil
Gemcitabine
Itraconazole
JAK1/JAK2 inhibitor
JAK1 inhibitor
JAK2 inhibitor
KIT inhibitor
MET inhibitor
MET inhibitor,type 1
Methotrexate
PDGFRA inhibitor
PDGFR inhibitor
PI3K/mTOR inhibitor
PI3K inhibitor
Paclitaxel
Palbociclib
Pemetrexed
RAF inhibitor
ROS1 inhibitor
Ruxolitinib
SMO inhibitor
SRC inhibitor
Sorafenib
VEGFR inhibitor
Vinorelbine
Vistusertib
YES1 inhibitor
anthracycline
antifolate
antimetabolite
cancer therapy
cancer therapy,ALK-targeting
cancer therapy,ATR-targeting
cancer therapy,BCR-ABL1-targeting
cancer therapy,CDK4-targeting
cancer therapy,CDK6-targeting
cancer therapy,CRAF-targeting
cancer therapy,EGFR-targeting
cancer therapy,FLT3-targeting
cancer therapy,JAK1-targeting
cancer therapy,JAK2-targeting
cancer therapy,KIT-targeting
cancer therapy,MET-targeting
cancer therapy,PDGFR-targeting
cancer therapy,PDGFRA-targeting
cancer therapy,PI3K-targeting
cancer therapy,RAF-targeting
cancer therapy,ROS1-targeting
cancer therapy,SMO-targeting
cancer therapy,SRC-targeting
cancer therapy,VEGFR-targeting
cancer therapy,YES1-targeting
cancer therapy,mTOR-targeting
cancer therapy,mTORC1-targeting
cancer therapy,mTORC2-targeting
cytotoxic chemotherapy
fluoropyrimidine
mTORC1/mTORC2 inhibitor
mTORC1 inhibitor
mTORC2 inhibitor
mTOR inhibitor
platinum-based antineoplastic agent
taxane
topoisomerase inhibitor
vinca alkaloid
+ PI3K/mTOR inhibitor
Head and neck cancer
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
Additional search terms:
API and Webpage URLs:
Copy /Bookmark
Filters
Recruitment Status
Recruiting (5)
Status unknown (1)
Recruitment Country and State
NSW (6)
QLD (5)
VIC (5)
SA (4)
WA (3)
NZ (1)
TAS (1)
Phase
Phase 1 / Phase 2 (1)
Phase 2 (1)
Phase 2 / Phase 3 (1)
Phase 3 (2)
Trial Type
Advanced (5)
Haem (1)
Paediatric (1)
Cancer Therapy Class
PI3K
83%
mTOR
83%
mTORC1
83%
mTORC2
83%
PI3K-delta
67%
PI3Kalpha
67%
CDK4
33%
CDK6
33%
KIT
33%
PDGFR
33%
VEGFR
33%
BCL2
17%
BTK
17%
CD20
17%
ER
17%
oestrogen axis
17%
FGFR
17%
FGFR1
17%
FGFR1/2/3
17%
FGFR2
17%
FGFR3
17%
FGFR4
17%
RET
17%
CTLA4
17%
PARP
17%
PD-1
17%
PD-1/PD-L1
17%
XPO1
17%
ALK
17%
ATR
17%
BCR-ABL1
17%
CRAF
17%
EGFR
17%
FLT3
17%
JAK1
17%
JAK2
17%
MET
17%
PDGFRA
17%
RAF
17%
ROS1
17%
SMO
17%
SRC
17%
YES1
17%
Facility
2170 - Liverpool - Liverpool Hospital (2)
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital (2)
2298 - Waratah - Calvary Mater Newcastle Medical Oncology (2)
3000 - Melbourne - Peter MacCallum Cancer Centre (2)
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre (2)
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre (2)
5042 - Bedford Park - Flinders Medical Centre (2)
2139 - Concord - Concord Repatriation General Hospital (1)
2560 - Campbelltown - Macarthur Cancer Therapy Centre - Campbelltown Hospital (1)
3004 - Melbourne, Southbank - Alfred Health (1)
4350 - Toowoomba - Toowoomba Hospital (1)
6005 - West Perth - Perth Blood Institute (1)
NZ.0622 - Takapuna - North Shore Hospital (1)
2031 - Randwick - Sydney Children's Hospital (1)
2145 - Westmead - The Children's Hospital at Westmead (1)
2305 - New Lambton Heights - John Hunter Children's Hospital (1)
3052 - Parkville - Royal Children's Hospital Melbourne (1)
3168 - Clayton - Monash Children's Hospital (1)
4101 - South Brisbane - Queensland Children's Hospital (1)
5006 - North Adelaide - Women's and Children's Hospital-Adelaide Cancer Centre (1)
6009 - Perth - Perth Children's Hospital (1)
2076 - Wahroonga - Sydney Adventist Hospital (1)
3065 - Fitzroy - St Vincent's Hospital Melbourne (1)
3199 - Frankston - Peninsula Health Frankston Hospital (1)
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre (1)
4215 - Southport - Gold Coast Private Hospital (1)
5006 - North Adelaide - Calvary North Adelaide Hospital, Adelaide Oncology & Haematology (1)
5011 - Woodville South - The Queen Elizabeth Hospital (1)
NA
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre (1)
3066 - Epping - Northern Hospital (1)
3168 - Clayton - Monash Medical Centre (1)
4102 - Woolloongabba - Princess Alexandra Hospital (1)
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre (1)
7000 - Hobart - Royal Hobart Hospital (1)
2050 - Camperdown - Chris O'Brien Lifehouse (1)
Cancer Type
Cancer
Solid tumour
Central nervous system cancer
Neurological cancer
Glioma
High-grade glioma
Malignant glioma
B-cell malignancy
Chronic lymphocytic leukaemia
Haematological malignancy
Leukaemia
Lymphoid leukaemia
Mature B-cell malignancy
Breast cancer
Glioblastoma
Anaplastic astrocytoma
Low-grade glioma
Head and neck cancer
URLs for this search
API URL:
Copy
Bookmarkable URL:
Copy